JP2017537881A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537881A5 JP2017537881A5 JP2017520314A JP2017520314A JP2017537881A5 JP 2017537881 A5 JP2017537881 A5 JP 2017537881A5 JP 2017520314 A JP2017520314 A JP 2017520314A JP 2017520314 A JP2017520314 A JP 2017520314A JP 2017537881 A5 JP2017537881 A5 JP 2017537881A5
- Authority
- JP
- Japan
- Prior art keywords
- biodegradable carrier
- anticonvulsant
- composition
- poly
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000001961 anticonvulsive agent Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 9
- 229920000642 polymer Polymers 0.000 claims description 4
- 229940125681 anticonvulsant agent Drugs 0.000 claims description 3
- 230000001773 anti-convulsant effect Effects 0.000 claims 7
- 229960003965 antiepileptics Drugs 0.000 claims 7
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 238000001704 evaporation Methods 0.000 claims 2
- 239000011859 microparticle Substances 0.000 claims 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims 2
- 229940065514 poly(lactide) Drugs 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 238000001694 spray drying Methods 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 239000008346 aqueous phase Substances 0.000 claims 1
- 229960000623 carbamazepine Drugs 0.000 claims 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 1
- 238000002296 dynamic light scattering Methods 0.000 claims 1
- 238000004945 emulsification Methods 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 230000008020 evaporation Effects 0.000 claims 1
- 229960002870 gabapentin Drugs 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 229960001816 oxcarbazepine Drugs 0.000 claims 1
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 claims 1
- 229960002036 phenytoin Drugs 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 229960001233 pregabalin Drugs 0.000 claims 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 229960004394 topiramate Drugs 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 206010010254 Concussion Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 230000000454 anti-cipatory effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 230000001535 kindling effect Effects 0.000 description 1
- 230000000936 membranestabilizing effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462081162P | 2014-11-18 | 2014-11-18 | |
| US62/081,162 | 2014-11-18 | ||
| PCT/US2015/017112 WO2016081022A1 (en) | 2014-11-18 | 2015-02-23 | Compositions for treating acute, post-operative, or chronic pain and methods of using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017537881A JP2017537881A (ja) | 2017-12-21 |
| JP2017537881A5 true JP2017537881A5 (enExample) | 2018-03-29 |
Family
ID=55960737
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017520314A Pending JP2017537881A (ja) | 2014-11-18 | 2015-02-23 | 急性、術後、または慢性疼痛を治療する組成物およびその使用方法 |
| JP2017526095A Pending JP2017533943A (ja) | 2014-11-18 | 2015-11-11 | 急性、術後、または慢性疼痛を治療する組成物およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017526095A Pending JP2017533943A (ja) | 2014-11-18 | 2015-11-11 | 急性、術後、または慢性疼痛を治療する組成物およびその使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20160136179A1 (enExample) |
| EP (2) | EP3220955A4 (enExample) |
| JP (2) | JP2017537881A (enExample) |
| CN (2) | CN107206097A (enExample) |
| AU (2) | AU2015350554A1 (enExample) |
| BR (2) | BR112017010430A2 (enExample) |
| CA (2) | CA2967287A1 (enExample) |
| IL (2) | IL251881A0 (enExample) |
| MX (2) | MX2017006388A (enExample) |
| WO (3) | WO2016081022A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170239183A1 (en) * | 2016-02-23 | 2017-08-24 | PixarBio Corporation | COMPOSITIONS COMPRISING NAv1.7 SELECTIVE INHIBITORS FOR TREATING ACUTE, POST-OPERATIVE, OR CHRONIC PAIN AND METHODS OF USING THE SAME |
| CN106902095B (zh) * | 2017-03-08 | 2021-11-05 | 东北林业大学 | 一种集化疗与免疫疗法为一体的载黄芩苷纳米制剂及其制备方法 |
| US20180338929A1 (en) * | 2017-05-23 | 2018-11-29 | Soon Kap Hahn | Method and Compounds for Treating Peripheral Neuropathy |
| US11571429B2 (en) * | 2017-05-23 | 2023-02-07 | Upexmed Co. Ltd. | Method and compounds for treating peripheral neuropathy |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166800A (en) * | 1977-08-25 | 1979-09-04 | Sandoz, Inc. | Processes for preparation of microspheres |
| IL86211A (en) * | 1987-05-04 | 1992-03-29 | Ciba Geigy Ag | Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation |
| US5948384A (en) * | 1990-09-14 | 1999-09-07 | Syngenix Limited | Particulate agents |
| US20030056896A1 (en) * | 1995-05-12 | 2003-03-27 | Frank Jao | Effective therapy for epilepsies |
| CN1156961A (zh) * | 1995-06-09 | 1997-08-13 | 欧罗赛铁克股份有限公司 | 产生长效局部麻醉的制剂和方法 |
| CA2547531C (en) * | 2002-11-26 | 2013-11-12 | Seacoast Neuroscience, Inc. | Buoyant polymer particles for delivery of therapeutic agents to the central nervous system |
| EP1781257B1 (en) * | 2004-08-13 | 2018-12-19 | Emisphere Technologies, Inc. | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent |
| BRPI0518829A2 (pt) * | 2004-12-06 | 2008-12-09 | Avigen Inc | mÉtodo para o tratamento de dor neuropÁtica e sÍndromes associadas |
| US20100204178A1 (en) * | 2006-10-02 | 2010-08-12 | James Cloyd | Novel parenteral carbamazepine formulation |
| WO2007120818A2 (en) * | 2006-04-12 | 2007-10-25 | Massachusetts Institute Of Technology | Compositions and methods for inhibiting adhesions |
| US20070253994A1 (en) * | 2006-04-28 | 2007-11-01 | Medtronic, Inc. | Intraspinal Drug Delivery Methods and Devices To Alleviate Chronic Pelvic Pain |
| JP5630998B2 (ja) * | 2006-05-15 | 2014-11-26 | マサチューセッツ インスティテュート オブ テクノロジー | 機能的粒子のためのポリマー |
| US20110052697A1 (en) * | 2006-05-17 | 2011-03-03 | Gwangju Institute Of Science & Technology | Aptamer-Directed Drug Delivery |
| GB0625322D0 (en) * | 2006-12-19 | 2007-01-24 | Pharmakodex Ltd | Pharmaceutical compositions |
| ES2689322T3 (es) * | 2008-03-04 | 2018-11-13 | Teva Pharmaceuticals International Gmbh | Métodos para tratar el dolor crónico |
| CN102083419A (zh) * | 2008-07-01 | 2011-06-01 | 日东电工株式会社 | 包含表面被覆了的微粒的医药组合物 |
| AU2010278601A1 (en) * | 2009-07-31 | 2012-02-23 | Xi'an Libang Medical Technology Co., Ltd | Nanosphere or microsphere drug carrier, preparation method, composition and use thereof |
| CN102348468B (zh) * | 2009-07-31 | 2014-11-05 | 西安力邦医药科技有限责任公司 | 微球药物载体、其制备方法、组合物及应用 |
| WO2012031205A2 (en) * | 2010-09-03 | 2012-03-08 | The Brigham And Women's Hospital, Inc. | Lipid-polymer hybrid particles |
| US9301946B2 (en) * | 2010-12-03 | 2016-04-05 | Warsaw Orthopedic, Inc. | Clonidine and GABA compounds in a biodegradable polymer carrier |
| EP2720699B1 (en) * | 2011-06-14 | 2018-05-16 | Hale Biopharma Ventures, Llc | Administration of benzodiazepine |
| CA2849378A1 (en) * | 2011-09-21 | 2013-03-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Nano delivery systems for sirna |
| JP2016501876A (ja) * | 2012-11-30 | 2016-01-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ステロイドの抗痙攣活性 |
| CN103610664B (zh) * | 2013-12-11 | 2015-09-16 | 中国药科大学 | 一种制备卡马西平聚乳酸-羟基乙酸共聚物微胶囊的方法 |
-
2015
- 2015-02-23 MX MX2017006388A patent/MX2017006388A/es unknown
- 2015-02-23 CN CN201580062137.2A patent/CN107206097A/zh active Pending
- 2015-02-23 US US14/628,563 patent/US20160136179A1/en not_active Abandoned
- 2015-02-23 AU AU2015350554A patent/AU2015350554A1/en not_active Abandoned
- 2015-02-23 WO PCT/US2015/017112 patent/WO2016081022A1/en not_active Ceased
- 2015-02-23 EP EP15861856.1A patent/EP3220955A4/en not_active Withdrawn
- 2015-02-23 BR BR112017010430A patent/BR112017010430A2/pt not_active IP Right Cessation
- 2015-02-23 CA CA2967287A patent/CA2967287A1/en not_active Abandoned
- 2015-02-23 JP JP2017520314A patent/JP2017537881A/ja active Pending
- 2015-11-11 CA CA2967335A patent/CA2967335A1/en not_active Abandoned
- 2015-11-11 AU AU2015350347A patent/AU2015350347A1/en not_active Abandoned
- 2015-11-11 BR BR112017010428A patent/BR112017010428A2/pt not_active Application Discontinuation
- 2015-11-11 WO PCT/US2015/060093 patent/WO2016081236A1/en not_active Ceased
- 2015-11-11 MX MX2017006422A patent/MX2017006422A/es unknown
- 2015-11-11 EP EP15861866.0A patent/EP3220917A4/en not_active Withdrawn
- 2015-11-11 JP JP2017526095A patent/JP2017533943A/ja active Pending
- 2015-11-11 CN CN201580062194.0A patent/CN107405351A/zh active Pending
- 2015-11-17 WO PCT/US2015/061066 patent/WO2016081445A1/en not_active Ceased
-
2016
- 2016-07-13 US US15/208,923 patent/US20160317446A1/en not_active Abandoned
-
2017
- 2017-04-24 IL IL251881A patent/IL251881A0/en unknown
- 2017-04-24 IL IL251880A patent/IL251880A0/en unknown
- 2017-04-25 US US15/496,827 patent/US20170224621A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Formation and stability of core–shell nanofibers by electrospinning of gel-like corn oil-in-water emulsions stabilized by gelatin | |
| Turk et al. | Formulation and optimization of nonionic surfactants emulsified nimesulide-loaded PLGA-based nanoparticles by design of experiments | |
| Tuomela et al. | Stabilizing agents for drug nanocrystals: effect on bioavailability | |
| Zhao et al. | Multifunctional folate receptor-targeting and pH-responsive nanocarriers loaded with methotrexate for treatment of rheumatoid arthritis | |
| Shenoy et al. | Poly (ethylene oxide)-modified poly (β-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs. 1. In vitro evaluations | |
| Pillai et al. | Folic acid conjugated cross-linked acrylic polymer (FA-CLAP) hydrogel for site specific delivery of hydrophobic drugs to cancer cells | |
| Frasco et al. | Transferrin surface‐modified PLGA nanoparticles‐mediated delivery of a proteasome inhibitor to human pancreatic cancer cells | |
| Mashabela et al. | A comprehensive review of cross-linked gels as vehicles for drug delivery to treat central nervous system disorders | |
| Wu et al. | In vitro study on anti-inflammatory effects of epigallocatechin-3-gallate-loaded nano-and microscale particles | |
| Jing et al. | Alendronate-decorated nanoparticles as bone-targeted alendronate carriers for potential osteoporosis treatment | |
| Stevanović et al. | A review of recent developments in biopolymer nano-based drug delivery systems with antioxidative properties: Insights into the last five years | |
| Lee et al. | Solid lipid nanoparticles loaded thermoresponsive pluronic–xanthan gum hydrogel as a transdermal delivery system | |
| Sharma et al. | Effects of curcumin-loaded poly (lactic-co-glycolic acid) nanoparticles in MDA-MB231 human breast cancer cells | |
| Andorko et al. | Impact of molecular weight on the intrinsic immunogenic activity of poly (beta amino esters) | |
| McCarron et al. | Celecoxib-loaded poly (D, L-lactide-co-glycolide) nanoparticles prepared using a novel and controllable combination of diffusion and emulsification steps as part of the salting-out procedure | |
| Fattahpour et al. | Design and optimization of alginate− chitosan− pluronic nanoparticles as a novel meloxicam drug delivery system | |
| JP2017537881A5 (enExample) | ||
| Romero et al. | Surface Engineered Poly (lactide-co-glycolide) Nanoparticles for Intracellular Delivery: Uptake and Cytotoxicity A Confocal Raman Microscopic Study | |
| Zewail | Folic acid decorated chitosan-coated solid lipid nanoparticles for the oral treatment of rheumatoid arthritis | |
| Thakker et al. | Inter-polymer complex microspheres of chitosan and cellulose acetate phthalate for oral delivery of 5-fluorouracil | |
| Michalak et al. | Polymeric nanoparticles–a novel solution for delivery of antimicrobial agents | |
| D’Addio et al. | Antitubercular nanocarrier combination therapy: Formulation strategies and in vitro efficacy for rifampicin and SQ641 | |
| Glinka et al. | Encapsulation of Amikacin into Microparticles Based on Low-Molecular-Weight Poly (lactic acid) and Poly (lactic acid-co-polyethylene glycol) | |
| Kilicay et al. | Concanavaline A conjugated bacterial polyester-based PHBHHx nanoparticles loaded with curcumin for breast cancer therapy | |
| Li et al. | Effects of mass ratio, pH, temperature, and reaction time on fabrication of partially purified pomegranate ellagitannin− gelatin nanoparticles |